News stories about MAXIMUS (NYSE:MMS) have trended somewhat positive on Sunday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MAXIMUS earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news headlines about the health services provider an impact score of 45.5576992569355 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of MAXIMUS (NYSE:MMS) traded down $0.99 during midday trading on Friday, hitting $67.78. The stock had a trading volume of 483,014 shares, compared to its average volume of 422,808. MAXIMUS has a 12-month low of $51.74 and a 12-month high of $72.71. The stock has a market capitalization of $4,420.81, a P/E ratio of 21.31, a price-to-earnings-growth ratio of 2.54 and a beta of 1.21.
MAXIMUS (NYSE:MMS) last issued its quarterly earnings results on Thursday, November 9th. The health services provider reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.04. The firm had revenue of $620.90 million for the quarter, compared to the consensus estimate of $606.86 million. MAXIMUS had a return on equity of 23.97% and a net margin of 8.54%. research analysts expect that MAXIMUS will post 3.05 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 28th. Shareholders of record on Thursday, February 15th will be issued a dividend of $0.045 per share. The ex-dividend date is Wednesday, February 14th. This represents a $0.18 annualized dividend and a yield of 0.27%. MAXIMUS’s payout ratio is currently 5.66%.
A number of equities analysts recently commented on the company. Canaccord Genuity reissued a “buy” rating on shares of MAXIMUS in a research note on Wednesday, December 27th. Zacks Investment Research raised MAXIMUS from a “sell” rating to a “hold” rating in a research note on Wednesday, January 17th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $65.60.
In other MAXIMUS news, insider Mark Andrekovich sold 5,594 shares of the stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $67.23, for a total transaction of $376,084.62. Following the sale, the insider now owns 27,996 shares of the company’s stock, valued at approximately $1,882,171.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel David Francis sold 3,900 shares of the stock in a transaction on Monday, November 13th. The shares were sold at an average price of $63.97, for a total value of $249,483.00. Following the sale, the general counsel now directly owns 15,090 shares in the company, valued at approximately $965,307.30. The disclosure for this sale can be found here. Insiders have sold a total of 71,417 shares of company stock worth $4,902,785 over the last 90 days. 3.10% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “MAXIMUS (NYSE:MMS) Earns Media Sentiment Score of 0.11” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/04/maximus-mms-receives-daily-coverage-optimism-rating-of-0-11.html.
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.